RJA
GILD icon

Raymond James & Associates’s Gilead Sciences GILD Stock Holding History

Raymond James & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-33,700
Closed -$718K – 3946
2022
Q4 		$718K Sell
33,700
-34,700
-51% -$2.75M ﹤0.01% 2638
2022
Q3 		$66K Sell
68,400
-11,900
-15% -$750K ﹤0.01% 3675
2022
Q2 		$120K Buy
80,300
+12,500
+18% +$774K ﹤0.01% 3644
2022
Q1 		$34K Buy
67,800
+22,100
+48% +$1.41M ﹤0.01% 3948
2021
Q4 		$26K Buy
45,700
+1,900
+4% +$131K ﹤0.01% 4007
2021
Q3 		$73K Buy
43,800
+10,700
+32% +$752K ﹤0.01% 3881
2021
Q2 		$19K Buy
33,100
+20,600
+165% +$1.38M ﹤0.01% 3981
2021
Q1 		$3K Buy
+12,500
New +$806K ﹤0.01% 3975
2020
Q3 		– Sell
-31,200
Closed -$33K – 3621
2020
Q2 		$33K Sell
31,200
-100
-0.3% -$7.66K ﹤0.01% 3416
2020
Q1 		$28K Sell
31,300
-900
-3% -$62.2K ﹤0.01% 3370
2019
Q4 		$19K Hold
32,200
– – ﹤0.01% 3617
2019
Q3 		$7K Sell
32,200
-2,600
-7% -$170K ﹤0.01% 3577
2019
Q2 		$31K Buy
34,800
+11,400
+49% +$750K ﹤0.01% 3537
2019
Q1 		$5K Sell
23,400
-200
-0.8% -$13.3K ﹤0.01% 3587
2018
Q4 		$3K Sell
23,600
-13,600
-37% -$951K ﹤0.01% 3502
2018
Q3 		$40K Buy
+37,200
New +$2.81M ﹤0.01% 3502
2017
Q4 		– Sell
-11,200
Closed -$30K – 3469
2017
Q3 		$30K Buy
+11,200
New +$856K ﹤0.01% 3280
2017
Q2 		– Sell
-10,600
Closed -$2K – 3373
2017
Q1 		$2K Sell
10,600
-6,100
-37% -$429K ﹤0.01% 3278
2016
Q4 		$35K Buy
16,700
+5,500
+49% +$409K ﹤0.01% 3113
2016
Q3 		$4K Buy
+11,200
New +$910K ﹤0.01% 3191
2015
Q3 		– Sell
-160,700
Closed -$1.58M – 2313
2015
Q2 		$1.58M Buy
160,700
+80,700
+101% +$8.82M 0.01% 1460
2015
Q1 		$448K Sell
80,000
-40,100
-33% -$4.07M ﹤0.01% 2083
2014
Q4 		$537K Sell
120,100
-158,100
-57% -$16.4M ﹤0.01% 1905
2014
Q3 		$3.21M Buy
278,200
+134,200
+93% +$13.1M 0.02% 841
2014
Q2 		$346K Buy
+144,000
New +$11.2M ﹤0.01% 1994

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Raymond James & Associates's GILD Position: Q3 2024 in Review

Raymond James & Associates increased its Gilead Sciences (GILD) stake by 4.7% in Q3 2024, buying an estimated $8.32M and bringing the position to 2,411,768 shares worth $202M. The position accounts for 0.12% of the portfolio, ranked #146.

Raymond James & Associates first reported a position in GILD in Q2 2013 and has held it in 46 quarters since. The position peaked at $243M in Q4 2022. 1,719 funds tracked by Wall St. Rank hold GILD as of Q3 2024.

  • Raymond James & Associates held 2,411,768 shares of Gilead Sciences worth $202M as of Q3 2024.
  • Raymond James & Associates bought 109,014 Gilead Sciences shares in Q3 2024, an estimated $8.32M.
  • Gilead Sciences made up 0.12% of Raymond James & Associates's portfolio in Q3 2024, its #146 holding.
  • Raymond James & Associates first reported a position in Gilead Sciences in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Gilead Sciences position peaked at $243M in Q4 2022.
  • 1,719 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.